File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00380-013-0327-0
- Scopus: eid_2-s2.0-84899053355
- WOS: WOS:000329942500005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS)
Title | Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS) |
---|---|
Authors | |
Keywords | Aged Cardiovascular Agents/*administration & dosage Coronary Angiography Coronary Restenosis/etiology Coronary Stenosis/radiography/*therapy *Drug-Eluting Stents Female Humans Male Middle Aged Myocardial Infarction/etiology Percutaneous Coronary Intervention/adverse effects/*instrumentation Prosthesis Design Retrospective Studies Sirolimus/administration & dosage/*analogs & derivatives Time Factors Treatment Outcome |
Issue Date | 2014 |
Citation | Heart and Vessels, 2014, v. 29 n. 1, p. 29-34 How to Cite? |
Abstract | The role of the second-generation zotarolimus-eluting stent RESOLUTE in small-vessel coronary artery disease is unclear. The aim of this study was examine the angiographic results of RESOLUTE in de novo coronary lesions of >/=50 % diameter stenosis in target vessels =2.5 mm. From August 2008 to April 2010, 142 symptomatic patients with 159 lesions who fitted the inclusion criteria were treated with RESOLUTE. The mean age of patients was 66 +/- 10 years, with male predominance (66 %). Diabetes mellitus was found in 62 (43.7 %) patients, whereas multivessel disease was observed in 105 (73.9 %). The mean stent size and length used were 2.33 +/- 0.13 and 22 +/- 8 mm, respectively. Follow-up angiography was performed on 143 (89.9 %) lesions in 127 (89.4 %) patients at a mean of 10.3 +/- 3.6 months. Angiographic restenosis was found in 9 (6.3 %) lesions; the late loss was 0.26 +/- 0.34 mm. At 1-year follow-up there were four cardiovascular deaths, two nonfatal myocardial infarctions, and six repeated revascularizations. The resultant major adverse cardiac event rate was 8.5 %. The use of RESOLUTE to treat small-vessel disease is associated with good clinical and angiographic outcomes at 1 year. |
Persistent Identifier | http://hdl.handle.net/10722/207701 |
ISSN | 2023 Impact Factor: 1.4 2023 SCImago Journal Rankings: 0.574 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jim, MH | en_US |
dc.contributor.author | Yiu, KH | en_US |
dc.contributor.author | Fung, RC | en_US |
dc.contributor.author | Ho, HH | en_US |
dc.contributor.author | Ng, AK | en_US |
dc.contributor.author | Siu, DCW | en_US |
dc.contributor.author | Chow, WH | en_US |
dc.date.accessioned | 2015-01-19T04:20:40Z | - |
dc.date.available | 2015-01-19T04:20:40Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Heart and Vessels, 2014, v. 29 n. 1, p. 29-34 | en_US |
dc.identifier.issn | 0910-8327 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/207701 | - |
dc.description.abstract | The role of the second-generation zotarolimus-eluting stent RESOLUTE in small-vessel coronary artery disease is unclear. The aim of this study was examine the angiographic results of RESOLUTE in de novo coronary lesions of >/=50 % diameter stenosis in target vessels </=2.5 mm. From August 2008 to April 2010, 142 symptomatic patients with 159 lesions who fitted the inclusion criteria were treated with RESOLUTE. The mean age of patients was 66 +/- 10 years, with male predominance (66 %). Diabetes mellitus was found in 62 (43.7 %) patients, whereas multivessel disease was observed in 105 (73.9 %). The mean stent size and length used were 2.33 +/- 0.13 and 22 +/- 8 mm, respectively. Follow-up angiography was performed on 143 (89.9 %) lesions in 127 (89.4 %) patients at a mean of 10.3 +/- 3.6 months. Angiographic restenosis was found in 9 (6.3 %) lesions; the late loss was 0.26 +/- 0.34 mm. At 1-year follow-up there were four cardiovascular deaths, two nonfatal myocardial infarctions, and six repeated revascularizations. The resultant major adverse cardiac event rate was 8.5 %. The use of RESOLUTE to treat small-vessel disease is associated with good clinical and angiographic outcomes at 1 year. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Heart and Vessels | en_US |
dc.subject | Aged | en_US |
dc.subject | Cardiovascular Agents/*administration & dosage | en_US |
dc.subject | Coronary Angiography | en_US |
dc.subject | Coronary Restenosis/etiology | en_US |
dc.subject | Coronary Stenosis/radiography/*therapy | en_US |
dc.subject | *Drug-Eluting Stents | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Myocardial Infarction/etiology | en_US |
dc.subject | Percutaneous Coronary Intervention/adverse effects/*instrumentation | en_US |
dc.subject | Prosthesis Design | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Sirolimus/administration & dosage/*analogs & derivatives | en_US |
dc.subject | Time Factors | en_US |
dc.subject | Treatment Outcome | en_US |
dc.title | Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS) | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yiu, KH: khkyiu@hku.hk | en_US |
dc.identifier.authority | Yiu, KH=rp01490 | en_US |
dc.identifier.doi | 10.1007/s00380-013-0327-0 | en_US |
dc.identifier.scopus | eid_2-s2.0-84899053355 | - |
dc.identifier.hkuros | 254855 | - |
dc.identifier.volume | 29 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 29 | en_US |
dc.identifier.epage | 34 | en_US |
dc.identifier.isi | WOS:000329942500005 | - |
dc.identifier.issnl | 0910-8327 | - |